Innovent Biologics (1801) announced that the National Medical Products Administration (NMPA) of China has accepted the company’s new drug application for its biosimilar product candidate to bevacizumab: IBI-305. This is the third new drug application from the company that has received approval from the NMPA.

IBI-305 is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody independently developed by the company; for the use of treating non-small cell lung cancer (NSCLC), colorectal cancer, and other malignant tumors. This new drug has been approved globally for the treatment of multiple types of malignant tumors including NSCLC and has a good safety profile as well as strong efficacy.